Table 3.
Baseline characteristics for men diagnosed as having metastasis after treatment, intermediate– high risk at cancer diagnosis
| Characteristic | Overall cohort | Propensity-matched cohort | ||||
|---|---|---|---|---|---|---|
| Irradiation, no. (%) (n = 1615) |
Radical prostatectomy, no. (%) (n = 301) |
SD* | Irradiation, no. (%) (n = 287) |
Radical prostatectomy, no. (%) (n = 287) |
SD* | |
| Age, yr | ||||||
| 66–69 | 315 ( 19.5) | 158 ( 52.5) | 0.7318 | 143 ( 49.8) | 144 ( 50.2) | 0.0070 |
| 70–74 | 633 ( 39.2) | 118 ( 39.2) | 0.0002 | 119 ( 41.5) | 118 ( 41.1) | 0.0071 |
| 75–79 | 471 ( 29.2) | 23 ( 7.6) | 0.5782 | 23 ( 8.0) | 23 ( 8.0) | 0 |
| ≥80 | 196 ( 12.1) | 2 ( 0.7) | 0.4821 | 2 (0.7) | 2 (0.7) | 0 |
| Race | ||||||
| White | 1389 ( 86.0) | 256 ( 85.1) | 0.0272 | 248 ( 86.4) | 244 ( 85.0) | 0.0398 |
| Black | 129 ( 7.9) | 33 ( 10.9) | 0.1017 | 30 ( 10.5) | 31 ( 10.8) | 0.0113 |
| Others | 97 ( 6.0) | 12 ( 3.9) | 0.0928 | 9 ( 3.1) | 12 ( 4.2) | 0.0557 |
| Year of diagnosis | ||||||
| 2000 or earlier | 758 (46.9) | 219 ( 72.8) | 0.5460 | 206 ( 71.8) | 205 (71.4) | 0.0077 |
| 2001 or later | 857 ( 53.1) | 82 ( 27.2) | 0.5460 | 81 ( 28.2) | 82 ( 28.6) | 0.0077 |
| Region | ||||||
| North central | 356 ( 22.0) | 65 ( 21.6) | 0.0109 | 65 ( 22.7) | 65 ( 22.7) | 0 |
| Northeast | 391 ( 24.2) | 30 ( 9.9) | 0.3854 | 32 ( 11.2) | 30 ( 10.5) | 0.0225 |
| South | 183 ( 11.3) | 34 ( 11.3) | 0.0011 | 32 ( 11.2) | 34 ( 11.9) | 0.0218 |
| West | 685 ( 42.4) | 172 ( 57.1) | 0.2978 | 158 ( 55.1) | 158 ( 55.1) | 0 |
| Comorbidity | ||||||
| 0 | 1246 ( 77.2) | 261 ( 86.7) | 0.2504 | 245 ( 85.4) | 247 ( 86.1) | 0.0199 |
| ≥1 | 369 ( 22.9) | 40 ( 13.3) | 0.2504 | 42 ( 14.6) | 40 ( 13.9) | 0.0199 |
| Cancer stage | ||||||
| T1 | 291 ( 18.0) | 55 ( 18.3) | 0.0066 | 42 ( 14.6) | 54 ( 18.8) | 0.1122 |
| T2a | 124 ( 7.7) | 25 ( 8.3) | 0.0231 | 14 ( 4.9) | 23 ( 8.0) | 0.1280 |
| ≥T2b | 1200 ( 74.3) | 221 ( 73.4) | 0.0201 | 231 ( 80.5) | 210 ( 73.2) | 0.1741 |
| Cancer grade Well differentiated |
27 (1.7) | 7 (2.3) | 0.0467 | 10 ( 3.5) | 7 ( 2.4) | 0.0617 |
| Moderately differentiated |
623 (38.6) | 132 (43.9) | 0.1074 | 138 ( 48.1) | 126 ( 43.9) | 0.0840 |
| Poorly differentiated State buy-in |
965 (59.8) | 162 (53.8) | 0.1200 | 139 ( 48.4) | 154 ( 53.7) | 0.1047 |
| No | 1466 (90.1) | 278 (92.4) | 0.0571 | 265 ( 92.3) | 266 ( 92.7) | 0.0132 |
| Yes | 149 (9.2) | 23 (7.6) | 0.0571 | 22 ( 7.7) | 21 ( 7.3) | 0.0132 |
SD = standardized difference.
*
SD = |P1 - P2| / square root of (P1[1 – P1] + P2[1 – P2] / 2). SDs are the same for all categorical variables with two levels.
Cancer grade: The Surveillance Epidemiology and End Results registry used a system of describing tumors as well differentiated, moderately differentiated, and poorly differentiated based on a Gleason score of 2–4, 5–7, and 8–10, respectively, before 2003. Starting in 2003, code 7 was reclassified from moderately differentiated to poorly differentiated.